Highlights

  • Algorae’s AlgoraeOS v1 independently validated by Victorian Centre for Functional Genomics showing predictive success in drug synergy.
  • Launch of enhanced AlgoraeOS v2 platform delivering superior accuracy and confidence-weighted predictions, with data expected in December 2025.
  • Study generated around 10,000 data points testing 84 drug-CBD-cell line combinations across established synergy models.

Shares of Algorae Pharmaceuticals Limited (ASX:1AI) rose 21.4% to 1.7 cents per share on 5 December 2025, following the announcement of independent preclinical validation results for its AI-driven drug combination prediction platform, AlgoraeOS v1 (AOS1). Conducted at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre, the validation demonstrated AOS1’s ability to prioritize synergistic drug combinations, supporting the platform’s use in future pharmaceutical discovery.

Independent Validation of AlgoraeOS v1 Demonstrates Predictive Capability

An independent study led by Professor Kaylene Simpson and Chief Scientific Officer Dr. James McKenna tested 21 drugs predicted by AOS1 to synergize with cannabidiol (CBD) across four cancer cell lines (T98G, BT20, PANC1, and 22Rv1). Approximately 10,000 data points were generated from 96 assessments covering 84 drug combinations using four recognized synergy models: Highest Single Agent (HSA), Bliss independence, Zero Interaction Potency (ZIP), and Loewe additivity.

The results showed that AOS1 effectively identified combinations confirmed as synergistic while excluding most non-synergistic pairs. This alignment with three of the four synergy models validates the platform’s potential for guiding drug combination prioritization.

Key Outcomes and Future Development

The validation program unveiled several potential drug combinations meeting predefined thresholds, now candidates for further preclinical evaluation. Consistent results across synergy models support the robustness of the predictions, though one model exhibited less correlation due to its sensitivity to dose-response assumptions.

Building on this foundation, Algorae has launched AlgoraeOS v2 (AOS2), a major platform upgrade developed alongside UNSW and CSIRO Data61. Trained on over 5.5 million inhibition records, AOS2 encompasses full dose-response modeling across synergy formalisms and delivers confidence-weighted predictions. Published benchmarks indicate AOS2 outperforms leading models, including those from Google DeepMind, advancing Algorae’s capabilities in AI-guided drug discovery. The first in silico predictions from AOS2 are expected in December 2025.

Strategic Impact and Next Steps

This independent validation marks a technical milestone for Algorae, confirming that AOS1 can effectively direct laboratory and R&D focus toward combinations with higher likelihoods of true biological synergy. The platform’s precision in differentiating synergistic from non-synergistic drug pairs informs efficient resource allocation in drug development.

Algorae plans to incorporate insights from the validation to refine scoring functions, models, and thresholds, and to optimize future preclinical program designs. The broader strategy includes leveraging AlgoraeOS to identify novel and repurposed drug combinations across oncology and other therapeutic areas in collaboration with research institutions and commercial partners.